Effects of Lactiplantibacillus plantarum GBCC_F0227 on Lipid Accumulation and Lipid Metabolism in High-Fat Diet-Induced Obese Mice

TL;DR

This study shows that Lactiplantibacillus plantarum GBCC_F0227 reduces lipid accumulation and inflammation in obese mice fed a high-fat diet.

Contribution

The study demonstrates the novel anti-obesity effects of Lactiplantibacillus plantarum GBCC_F0227 in both cell and mouse models.

Findings

GBCC_F0227 reduced triglyceride accumulation and lipid metabolism gene expression in 3T3-L1 adipocytes.

In mice, GBCC_F0227 lowered body weight, adipose tissue expansion, and inflammatory markers in white adipose tissue.

GBCC_F0227 also reduced hepatic lipid accumulation and Pparg and Cd36 gene expression in the liver.

Abstract

Obesity is characterized by excessive lipid accumulation and chronic inflammation that disrupt metabolic homeostasis. This study investigated the effects of Lactiplantibacillus plantarum GBCC_F0227 on lipid metabolism using differentiated 3T3-L1 adipocytes and a high-fat diet (HFD)-induced obese mouse model. In 3T3-L1 adipocytes, exposure to GBCC_F0227 culture supernatant was associated with reduced intracellular triglyceride accumulation and lower expression of lipid metabolism-related genes. Consistent with the in vitro observations, oral administration of GBCC_F0227 attenuated body weight gain and adipose tissue expansion in HFD-fed mice, together with lower expression of HFD-induced lipid metabolism-related genes (Pparg, Fabp4, Dgat2, and Cs) in white adipose tissue (WAT). GBCC_F0227 treatment also reduced the expression of inflammatory markers (Il-6, Il-1b) as well as Leptin, in epididymal WAT. In the liver, GBCC_F0227 administration lowered the expression of Pparg and Cd36 and reduced hepatic lipid accumulation. Collectively, these findings indicate that GBCC_F0227 administration is associated with coordinated changes in lipid accumulation and lipid metabolism-related gene expression in WAT and liver under HFD conditions. These results highlight the potential of GBCC_F0227 as a probiotic candidate for modulating obesity-associated lipid metabolic alterations.

Figures